Vaccines against Enveloped RNA Viruses
A special issue of Viruses (ISSN 1999-4915). This special issue belongs to the section "Viral Immunology, Vaccines, and Antivirals".
Deadline for manuscript submissions: closed (15 December 2023) | Viewed by 306
Special Issue Editor
Interests: Japanese encephalitis virus; flavivirus; porcine reproductive and respiratory syndrome virus; arterivirus; replication; virus–host interactions; pathogenesis; vaccine
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
A wide variety of viruses have posed a clear threat to human and animal health throughout history, and ongoing outbreaks of viral infection are still continuously occurring across the globe. In recent years, most viral outbreaks have been caused by a group of enveloped RNA viruses, including the Zika, dengue, yellow fever, Chikungunya, severe acute respiratory syndrome, Middle East respiratory syndrome, influenza, Crimean-Congo hemorrhagic fever, Rift Valley fever, Ebola, Marburg, Nipah, Hendra, and Lassa viruses. These emerging and re-emerging viruses can cause severe and even lethal disease in humans and/or animals. Unlike passive preventive measures to avoid exposure to these viruses, vaccination is the most cost-effective strategy for providing long-term protective immunity. Therefore, basic and translational research on the development of vaccines against these pathogens is of high priority. This Special Issue seeks to gather manuscripts (including reviews, research articles, and short communications) to highlight scientific achievements related to promising experimental vaccines against emerging and re-emerging enveloped RNA viruses, as well as old, conventional vaccines against the most widespread enveloped RNA viruses. In particular, we are interested in new vaccine platforms that are applicable to multiple pathogens. This Special Issue will provide an open access platform for exchanging past and current vaccine research and development.
Dr. Young-Min Lee
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- enveloped RNA viruses
- emerging viruses
- vaccines
- Zika virus
- SARS-CoV-2
- influenza virus
